Immutep Announces Data Presentations at Upcoming Industry Conferences


SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at two industry conferences in October and November 2019.

Conference:World Immunotherapy Congress as part of Festival of Biologics 2019
Dates:October 15-17, 2019 (Tuesday, 15th October/ 2.50 p.m. CET)
Venue:Basel Congress Centre, Basel, Switzerland
Presentation Title:A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology – mature results of TACTI-mel
Presenter:Frédéric Triebel, CSO & CMO of Immutep

Conference:34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Dates:November 6-10, 2019 (Friday, November 8th, 7.00am – 8.00pm EST)
Venue:Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA
Title:Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab
Poster Number:343
Authors:J. Peguero, E. Felip, B. Doger, M. Marjem, E. Carcereny, T. Clay, P. Bajaj, M. Krebs, F. Triebel

All presentations will be made available on the Company’s website at

About Immutep

Further information can be found on the Company’s website or by contacting:

U.S. Investors:
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404;

Garth Russell, LifeSci Advisors
+1 (646) 876-3613;

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105;